Who are AK112, Carboplatin, Paxlitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab + Relatlimab, BAT2206, AK112, Gemcitabine, Cisplatin, TAR-210, Nivolumab-relatlimab FDC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ak112-carboplatin-paxlitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AK112, Carboplatin, Paxlitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AK112, Carboplatin, Paxlitaxel (AK112, Carboplatin, Paxlitaxel) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination. Area: Oncology.

phase 3 Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination PD-1 and LAG-3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK112, Carboplatin, Paxlitaxel (AK112, Carboplatin, Paxlitaxel) — Akeso. AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AK112, Carboplatin, Paxlitaxel TARGET	AK112, Carboplatin, Paxlitaxel	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination	PD-1 and LAG-3
Nivolumab + Relatlimab	Nivolumab + Relatlimab	H. Lee Moffitt Cancer Center and Research Institute	marketed	Dual checkpoint inhibitor (PD-1 and LAG-3 inhibitor combination)	PD-1 and LAG-3
BAT2206	BAT2206	Bio-Thera Solutions	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)
AK112, Gemcitabine, Cisplatin	AK112, Gemcitabine, Cisplatin	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy	PD-1 and LAG-3
TAR-210	TAR-210	Janssen Research & Development, LLC	phase 3	Bispecific antibody	PD-1 and LAG-3
Nivolumab-relatlimab FDC	Nivolumab-relatlimab FDC	Bristol-Myers Squibb	phase 3	Dual checkpoint inhibitor (PD-1/LAG-3)	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination class)

Akeso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK112, Carboplatin, Paxlitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/ak112-carboplatin-paxlitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab